Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,580.06
(
0.22%
)
US TECH 100
29,506.00
(
0.28%
)
Dow Jones
51,032.46
(
0.72%
)
Brent Oil
91.36
(
0.00%
)
Bitcoin
73,796.99
(
0.59%
)
News Focus
News Focus
Post# of 257660
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 123038
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: RockRat post# 221543

Monday, 10/22/2018 5:04:23 PM

Monday, October 22, 2018 5:04:23 PM

Post# of 257660
NTGN—I concur with the viewpoint in your Twitter link, even while recognizing that the tweeter is an executive at a potentially competing company. Not testing monotherapy in phase-1 is curious, to say the least.

A cynic might say that NTGN didn’t examine NEO-PV-1 single-agent activity because they did not expect any, based on preclinical data.

Meanwhile… GRTS is hovering close to its IPO price after the unexplained pop last week.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today